Janux Therapeutics, Inc.
JANX
$17.11
$1.257.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,177.90% | -- | -- | -100.00% | -82.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,177.90% | -- | -- | -100.00% | -82.56% |
| Cost of Revenue | 71.15% | -- | 78.07% | 69.97% | -80.04% |
| Gross Profit | 406.82% | -- | -95.47% | -112.74% | 79.36% |
| SG&A Expenses | -39.88% | 33.67% | 34.03% | 29.24% | 174.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.72% | 98.59% | 62.97% | 56.05% | 97.93% |
| Operating Income | 1.65% | -226.42% | -73.09% | -79.85% | -126.66% |
| Income Before Tax | 13.35% | -468.18% | -59.27% | -71.93% | -142.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.35% | -468.18% | -59.27% | -71.93% | -142.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.35% | -468.18% | -59.27% | -71.93% | -142.56% |
| EBIT | 1.65% | -226.42% | -73.09% | -79.85% | -126.66% |
| EBITDA | 1.65% | -234.76% | -75.14% | -82.69% | -130.73% |
| EPS Basic | 23.68% | -400.00% | -26.42% | -41.21% | -102.92% |
| Normalized Basic EPS | 23.68% | -399.71% | -26.42% | -41.23% | -102.91% |
| EPS Diluted | 23.68% | -400.00% | -26.42% | -41.21% | -102.92% |
| Normalized Diluted EPS | 23.68% | -399.71% | -26.42% | -41.23% | -102.91% |
| Average Basic Shares Outstanding | 13.54% | 13.68% | 25.98% | 21.74% | 19.52% |
| Average Diluted Shares Outstanding | 13.54% | 13.68% | 25.98% | 21.74% | 19.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |